GlassScriptPhysician profile
Ashley A Little
NPI 1770705121
$2,980.22
in general payments reported to CMS, 2019-2025
32 companies · $763 in 2025
The $763 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $629 · 2023: $537 · 2024: $796 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $558.84 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $321.66 | 2022-2025 | Breztri, Farxiga, Fasenra |
| Abbvie INC. | $230.40 | 2021-2025 | |
| Novo Nordisk INC | $227.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.74 | 2021-2025 | Jardiance, Ofev, Tradjenta |
| Amgen INC. | $158.43 | 2022-2024 | Repatha, Otezla |
| Dexcom, INC. | $157.02 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $120.13 | 2021-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $97.18 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $91.26 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $76.20 | 2021-2022 | |
| Pfizer INC. | $76.17 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $75.67 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.94 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $60.60 | 2024-2025 | Spravato |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $59.24 | 2023-2024 | Briviact |
| Bayer Healthcare Pharmaceuticals INC. | $49.65 | 2023-2024 | |
| Dynavax Technologies Corporation | $41.35 | 2023 | Heplisav-B |
| Abbott Laboratories | $39.22 | 2025 | Freestyle Libre |
| Verona Pharma, INC. | $36.45 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $32.34 | 2022 | |
| Mylan Specialty L.P. | $32.24 | 2022-2024 | Yupelri |
| Vanda Pharmaceuticals INC. | $29.20 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $29.20 | 2022 | |
| Genzyme Corporation | $22.96 | 2025 | |
| Boston Scientific Corporation | $22.75 | 2023 | Bodyguardian |
| Phathom Pharmaceuticals, INC. | $21.04 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $20.39 | 2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $20.28 | 2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $15.80 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.81 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $14.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.